Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
News about Amgen Inc. (AMGN) centers on its biotechnology medicines, clinical milestones, corporate transactions and investor communications. The company describes itself as discovering, developing, manufacturing and delivering medicines for cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases, and its news flow reflects activity across these therapeutic areas.
Investors following AMGN news can see updates on regulatory decisions and clinical data for key products. Recent announcements include U.S. Food and Drug Administration approvals and label expansions, such as full approval for IMDELLTRA (tarlatamab-dlle) in extensive stage small cell lung cancer after progression on platinum-based chemotherapy, and approval of UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor and anti-MuSK antibody positive. Amgen has also reported landmark cardiovascular outcomes data for Repatha (evolocumab) from the VESALIUS-CV trial.
Corporate development and pipeline news are another focus. Amgen has announced the acquisition of Dark Blue Therapeutics, a biotechnology company developing targeted protein degraders for oncology, adding an investigational MLLT1/3-targeting molecule for acute myeloid leukemia to its portfolio. The company also issues releases on capital allocation decisions, such as dividend declarations, and on participation in major healthcare investment conferences where management discusses business developments.
This AMGN news page allows readers to track company press releases and related coverage, including clinical trial readouts, FDA decisions, acquisitions, pricing and access initiatives, and presentations at scientific and investor meetings. Users interested in biotechnology, oncology innovation, cardiovascular outcomes and large-cap healthcare equities can monitor these updates as part of their ongoing research on Amgen stock.
Amgen (NASDAQ: AMGN) reported promising Phase 1b results from the CodeBreaK 101 study, showcasing a median progression-free survival (PFS) of 5.7 months in patients with KRAS G12C-mutated colorectal cancer. The combination of LUMAKRAS® (sotorasib) and Vectibix® (panitumumab) achieved a 30% confirmed objective response rate in heavily pre-treated patients. Among 40 participants, 92.5% experienced disease control, and tumor shrinkage was observed in 88%. The study emphasizes the need for effective treatments in this challenging patient population.
LUMAKRAS (sotorasib) demonstrates significant progress in treating KRAS G12C-mutated non-small cell lung cancer (NSCLC) according to results from the Phase 3 CodeBreaK 200 trial. At one year, 25% of patients on LUMAKRAS experienced progression-free survival (PFS) compared to 10% for docetaxel. Additionally, the objective response rate (ORR) was **28%** for LUMAKRAS versus **13%** for docetaxel. Fewer treatment-related adverse events were reported with LUMAKRAS, reinforcing its potential as a key treatment option. Amgen plans to submit these findings to global health authorities.
Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 2022 Global Healthcare Conference on Sept. 13, 2022, at 9:10 a.m. ET. CEO Robert A. Bradway will lead the discussion. The event will be webcasted live and accessible to the public. Recorded presentations and updates about Amgen can be found on their website under the Investors section. Amgen, a biotechnology leader since 1980, focuses on innovative therapeutics for serious illnesses, and is part of the Dow Jones Industrial Average and Nasdaq-100 index.
Amgen announced positive results from two Phase 3 studies of Otezla (apremilast) presented at the 31st EADV Congress. The SPROUT study showed significant efficacy in pediatric patients aged 6-17 with moderate to severe plaque psoriasis, achieving a 33.1% response compared to 11.5% for placebo at week 16 (P<0.0001). The DISCREET study demonstrated improvements in adult genital psoriasis, with 38.7% achieving a clear response versus 19.1% for placebo (P=0.0003). Adverse events were consistent with Otezla's established safety profile.
Amgen (NASDAQ:AMGN) will host a webcast for the investment community on Sept. 12, 2022, at 1:30 p.m. ET, during the European Society for Medical Oncology Annual Congress (ESMO). Dr. David M. Reese and Amgen's clinical team will discuss findings from the LUMAKRAS® (sotorasib) CodeBreaK 200 study in non-small cell lung cancer, as well as the Phase 1b expansion of LUMAKRAS with Vectibix® (panitumumab) in colorectal cancer. The webcast will be available to the media, investors, and the public, and archived for 90 days on Amgen's website.
Amgen (NASDAQ:AMGN) will present at Wells Fargo's 2022 Global Healthcare Conference on September 8, 2022, at 9:45 a.m. ET. The presentation will feature David M. Reese, M.D. and Peter H. Griffith, executives of the company. A live webcast will be available to investors and the public, with archival access for 90 days. Amgen aims to improve health outcomes through innovative therapeutics, leveraging advanced human genetics. As a significant player in biotechnology, Amgen is included in the Dow Jones Industrial Average and Nasdaq-100 indices.
Amgen will present at Citi's 2022 Global Healthcare Conference on September 7, 2022, at 8:50 a.m. ET. David M. Reese, M.D., and Peter H. Griffith will represent the company. The presentation will be webcast live for the media, investors, and the public, with an archive available for at least 90 days post-event. Amgen is a biotechnology leader, focusing on innovative therapies and high unmet medical needs. The company is part of the Dow Jones Industrial Average and the Nasdaq-100 index, recognized for its workplace culture and sustainability efforts.
Amgen announced that LUMAKRAS (sotorasib) met its primary endpoint of progression-free survival in the Phase 3 CodeBreaK 200 trial, outperforming standard treatment with docetaxel in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). The study involved 345 patients who had previously undergone standard chemotherapy and checkpoint inhibitor therapy. Further data will be shared at an upcoming medical congress. LUMAKRAS is approved in over 44 global markets, addressing a critical need for effective treatments in this patient population.
Amgen (AMGN) announced promising results from the Phase 3 SPROUT trial for Otezla (apremilast) in children aged 6-17 with moderate to severe plaque psoriasis. The positive outcomes will be shared at the EADV conference in Milan, Italy, on Sept. 7-10, 2022. Additional results from the Phase 3 DISCREET study on genital psoriasis will also be presented. Further highlights include analyses on rocatinlimab for atopic dermatitis. Amgen emphasizes its commitment to addressing treatment gaps for patients with autoimmune skin diseases.
Amgen presented new data on Repatha (evolocumab) at the ESC 2022, indicating a 20% relative risk reduction in major cardiovascular events and a 23% reduction in cardiovascular deaths for patients treated with Repatha compared to placebo. The Phase 3 FOURIER-OLE studies involved 6,635 patients and showed that 80% achieved LDL-C levels 55 mg/dL at Week 12. The long-term study confirmed the drug's tolerability over , underscoring the importance of early LDL-C lowering in reducing cardiovascular risk.